MedTrace Logo

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07149649 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-03-27

No results posted yet for this study

Summary

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.

Conditions

  • Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions

DRUG

Magnesiocard

2.5 mmol film-coated tablets in addition to standard first line therapy

DRUG

Magnesium Diasporal

4 mmol IV formulation in addition to standard first line therapy

OTHER

Microcrystalline cellulose

Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy

OTHER

Isotonic saline solution 0.9%

Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Jonas Lötscher, MD, PhD · CH - Universitätsspital Basel

  • Sacha Rothschild, Prof MD, PhD · CH - Kantonsspital Baden

  • Christoph Hess, Prof MD, PhD · CH - Universitätsspital Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2031-01-01
Completion
2035-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07149649 on ClinicalTrials.gov